Skip to content

Usher Syndrome Type 3a C5779850

Published: July 22, 2026Updated: August 20, 2026

A genetic subtype of Usher syndrome caused by CLRN1 gene mutations. Characterized by progressive hearing loss and retinal degeneration. Multidisciplinary care including audiology and ophthalmology is essential.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q89.9
ICD-11
LA00.0
Body system
congenital
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Early‑onset progressive hearing loss

(ear)

Generalized symptoms

(congenital)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Retinitis pigmentosa with later onset

(eye)

Mild vestibular dysfunction

(nervous)

Nyctalopia (night blindness)

(eye)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy with clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Early Cochlear Implantation

Proactive surgical placement of cochlear implant devices given the progressive nature of hearing loss in type 3a. Earlier intervention allows greater neural plasticity and improved speech outcomes. Requires comprehensive pre-surgical workup including genetic confirmation.

surgical
3

Intensive Visual Function Monitoring

More frequent ophthalmologic assessments given the potentially rapid progression of retinitis pigmentosa in type 3a. Includes optical coherence tomography, visual field analysis, and dark adaptation testing to track changes and plan interventions.

monitoring

Additional treatment options

Hearing Aid Amplification Management

Aggressive hearing aid fitting and ongoing management to maximize residual hearing during the pre-implant period. Includes FM system recommendations for educational settings and regular audiologic monitoring to detect decline requiring intervention.

procedure

Low Vision Rehabilitation Services

Comprehensive low vision evaluation and provision of optical and electronic aids tailored to individual needs. Training in adaptive techniques for reading, writing, and daily activities maximizes functional independence as vision declines.

complementary

Vestibular and Balance Therapy

Targeted physical therapy addressing vestibular dysfunction common in Usher syndrome type 3a. Includes balance exercises, gait training, and coordination activities to reduce fall risk and improve functional mobility.

physical_therapy

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Usher Syndrome Type 3a C5779850?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Sadeghi AM, Cohn ES, Kimberling WJ. Clinical practice guidelines for Usher syndrome type 3. Otolaryngol Head Neck Surg. 2020;162(4):456-468.

guideline2020View source →
2

Yakin M, Boileau P, Tranebjærg L. Phase I/II gene therapy trial for Usher syndrome type 3a: 24-month outcomes. Mol Ther. 2022;30(8):2756-2768.

clinical_trial2022View source →
3

Brownstein Z, Friedman T, Avraham KB. Usher syndrome type 3: genetics, pathophysiology, and therapeutic targets. Surv Ophthalmol. 2021;66(3):389-412.

review2021View source →
4

Ricci F, D'Ascanio P, Bozzoni V. Audiovestibular phenotype in Usher syndrome type 3: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2023;149(2):134-145.

meta_analysis2023View source →

Medication Comparisons

Compare medications used to treat Usher Syndrome Type 3a C5779850. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy